• Science & Technology
• Health & Medicine

Blocking a survival mechanism could tackle melanoma treatment resistance

Researchers have demonstrated an approach which, used in parallel with existing treatments, wipes out the ‘survival system’ of cancer cells. Researchers have demonstrated an approach which, used in parallel with existing treatments, wipes out the ‘survival system’ of cancer cells.

14 November 2019

• Science & Technology
• Health & Medicine

Trial to test new treatment combination for children and adults with leukaemia

A clinical trial testing a new treatment combination in patients with leukaemia launches through the Combinations Alliance today. A clinical trial testing a new treatment combination in patients with leukaemia launches through the Combinations Alliance today.

30 May 2018

• Science & Technology

Cancer Research UK and the Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance

Cancer Research UK and The Institute of Cancer Research, London announce a multi-project collaboration and licensing deal with Merck. Cancer Research UK and The Institute of Cancer Research, London announce a multi-project collaboration and licensing deal with Merck.

17 January 2018

• Science & Technology

Cancer Research UK announces drug discovery collaboration with Celgene Corporation

Cancer Research UK announces the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology, and Celgene Corporation Cancer Research UK announces the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology, and Celgene Corporation

15 December 2017

• Science & Technology
• Health & Medicine

Experimental drug trial seeks to improve treatment for head and neck cancer

A trial to test an experimental drug in patients with head and neck cancer launches in the UK through the Combinations Alliance. A trial to test an experimental drug in patients with head and neck cancer launches in the UK through the Combinations Alliance.

24 November 2017

• Science & Technology
• Health & Medicine

Scientists exploit leaks in blood brain barrier to treat glioblastoma

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma. An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma.

6 November 2017

• Science & Technology
• Health & Medicine

Cancer Research UK launches trial to test new drug in patients with advanced cancer

A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK today. A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK today.

23 August 2017

• Science & Technology
• Health & Medicine

New bladder cancer therapy to start clinical trials

An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement signed today. An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement signed today.

26 June 2017

• Science & Technology

Hitgen and Cancer Research UK’s Manchester Institute enter licence agreement in lung cancer

Cancer Research UK, Cancer Research Technology and HitGen Ltd have entered into a licence agreement to develop a novel class of drugs in lung cancer. Cancer Research UK, Cancer Research Technology and HitGen Ltd have entered into a licence agreement to develop a novel class of drugs in lung cancer.

28 February 2017

• Science & Technology

Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies

Cancer Research Technology, Tusk Therapeutics and UCL have signed an agreement to research, develop and commercialise an antibody-based therapeutic. Cancer Research Technology, Tusk Therapeutics and UCL have signed an agreement to research, develop and commercialise an antibody-based therapeutic.

7 February 2017

• Science & Technology

Cancer Research Technology pioneer fund announces investment in blood cancer drugs

The Cancer Research Technology (CRT) Pioneer Fund announced an investment to develop a promising new class of drugs for blood cancer. The Cancer Research Technology (CRT) Pioneer Fund announced an investment to develop a promising new class of drugs for blood cancer.

9 December 2016

• Science & Technology

CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration

Cancer Research Technology (CRT) has today received a success payment from GlaxoSmithKline resulting from its research collaboration. Cancer Research Technology (CRT) has today received a success payment from GlaxoSmithKline resulting from its research collaboration.

6 October 2016